This mid-year tool offers a quick, evidence-based resource for medical and pharmacy directors for some of the new FDA approvals to help guide their benefit design decision-making and the development of formulary and other drug coverage criteria.
This new mid-year Addendum includes a select sample of comprehensive updates on some of the key new drugs approved by the FDA in 2019, as well as several new and important indications for drugs that are already on the market. This new feature provides a preview to the full annual guide that will be published early next year.
We hope you find this new publishing effort a useful tool for applying up-to-date information on new pharmaceuticals to benefit design decisions and patient care.
EDITOR’S NOTE: The FDA continues to make changes to the prescribing information of many drugs on an ongoing basis. The information in this Addendum is based on each drug’s prescribing information up to July 10, 2019. The Publisher and the Editors are not responsible for any inaccuracies stemming from labeling changes, new approvals, or company updates that became available after that date. Readers are advised to review the most recent prescribing information for any future updates and revisions.